Anbio Biotechnology: Risky Valuation Concerns As COVID-Related Sales Decline
Source: SeekingAlpha
2025-06-05 10:58:01 ET
...
Read the full article on Seeking Alpha
For further details see:
Anbio Biotechnology: Risky Valuation Concerns As COVID-Related Sales Decline
Anbio Biotechnology
NASDAQ: NNNN
NNNN Trading
-8.76% G/L:
$20.61 Last:
32,239 Volume:
$21.51 Open:
NNNN Latest News
August 08, 2025 09:05:14 pm
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
May 15, 2025 01:05:47 am
Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions
March 07, 2025 09:10:00 am
Investorideas.com adds New IPOs in Biotech, Technology, Homebuilder, Aerospace, Sports
